



Investor Information

Ticker Symbol
WUHN

Reporting Status
Alternative Reporting Standard
Unaudited

OTC Marketplace
Pink Sheet Current

Recent Share Price
.025

52 Week Range
0.017 - 0.485

Authorized Shares 100,000,000

Outstanding Shares 4,171,310

Market Cap
\$ 1,817,783

State of Incorporation
Nevada

Transfer Agent
Corporate Stock Transfer, Inc.

Chief Executive Officer
Jeff Robinson

Chief Medical Officer
Dr. Anna Morera Leralta

Corporate Headquarters
6500 Transcanada hwy
Suite 400, Pointe-Claire, Qc
H9R 0A5

**Very well
positioned for
strategic growth
in 2020**

COMMITTED TO CBD & PSILOCYBIN SCIENCE!

~~00057/222626~~

~~1&3\$. 22357~~

~~656&.01&2&%~~

Wuhan General Group, Inc. through its wholly owned subsidiary MJ MedTech is a cosmetics and food for special medical purposes (FSMP) company with leading alternative plant-based cannabinoids and psilocybin medical research, formulation and delivery system divisions. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies.

The Company's research and development is focus on chronic and inflammatory diseases new therapies to help patients who suffer from inflammatory bowel syndrome, arthritis, chronic respiratory diseases, seizure disorder, migraine, sleeping disorders, cancer, obesity, diabetes and many other conditions. Cannabinoids-based products are under the Dr. AnnaRx and Medspresso brands. In addition, its established division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients diagnosed with mental health disorders, Alzheimer's, Parkinson's, major depressive disorder, drug and alcohol addiction, cardiovascular diseases and PTSD.

The Company is currently positioning itself to become a major player in the estimated 146.4 billion dollars medical cannabinoids space as well as the promising psilocybin market. The international growing cannabinoids and psilocybin market for medical applications is expected to propel revenue growth in Canada, the United States, South Africa and Europe.

WUHN Subsidiaries

Cosmetics and food for special medical purposes (FSMP) company with leading alternative plant based cannabinoids and psilocybin medical research, formulation and delivery system divisions.



Medspresso™ is founded on the philosophy of combining health benefits with our three E's : Extraordinary, Exquisite and Elegant. All premium beverages are served in environmentally friendly packaging.



Doctor Anna Morera Leralta and her team of molecular research scientists have created the ultimate CBD-infused beauty and health line. Dr. AnnaRx™ products are formulated with pharmaceutical premium grade CBD, all-natural ingredients and are gender neutral.



M2BIO is researching and developing indications for psilocybin new therapies, through clinical trials, that will help patients who suffer from mental illness, drug and alcohol addiction, Alzheimer's and Parkinson's.

This document may contain forward-looking statements, including information about future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release other than those of historical fact, about an action, event or development, are forward looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results to be materially different than those expressed or implied in such statements. StockVest was paid 500,000 restricted shares by WUHN on 4/06/2020 for 90 days of services.